Suppr超能文献

阿曼射血分数降低的心力衰竭患者的指南指导药物治疗:使用情况、未处方原因及剂量优化

Guideline-directed medical therapy in heart failure patients with reduced ejection fraction in Oman: utilization, reasons behind non-prescribing, and dose optimization.

作者信息

Al-Aghbari Safiya, Al-Maqbali Juhaina Salim, Alawi Abdullah M Al, Za'abi Mohammed Al, Al-Zakwani Ibrahim

机构信息

MSc. Department of Pharmacology & Clinical Pharmacy, College of Medicine & Health Sciences, Sultan Qaboos University, Muscat, Oman.

MSc. Department of Pharmacy, Sultan Qaboos University Hospital, Muscat, Oman.

出版信息

Pharm Pract (Granada). 2022 Apr-Jun;20(2):2642. doi: 10.18549/PharmPract.2022.2.2642. Epub 2022 Apr 13.

Abstract

BACKGROUND OBJECTIVE

To determine the reasons behind guideline-directed medical therapy (GDMT) non-prescribing, drug utilization before and after excluding those intolerable to GDMT, as well as dose optimization in heart failure (HF) patients with reduced ejection fraction (<40%) (HFrEF) in Oman.

METHODS

The study included HF patients seen at the medical outpatient clinics at Sultan Qaboos University Hospital, Muscat, Oman, between January 2016 and December 2019 and followed up until the end of June 2021. The use of renin-angiotensin-system (RAS) blockers (angiotensin-converting-enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) or angiotensin receptor-neprilysin inhibitors (ARNIs)), beta blockers and mineralocorticoid receptor antagonists (MRAs) were evaluated as per the European, American, and Canadian HF guidelines. Analyses were performed using univariate statistics.

RESULTS

A total of 171 HFrEF patients were enrolled for this study, the overall mean age of the cohort was 63 ± 15 years old and 59% were male. Over 65% of the patients had chronic kidney disease. Almost 55% of the patients were intolerable to GDMT. The proportion of patients on beta blockers, RAS blockers/ hydralazine-isosorbide dinitrate combination, and MRAs, before and after excluding those intolerable to GDMT, were 89%, 97%, and 77%, and, 94%, 47% and 85%, respectively, while the proportion of patients on the GDMT combination concomitantly was 41% and 83%, respectively. A total of 61%, 44% and 100% of the patients were prescribed ≥50% of the target dose for beta blockers, RAS blockers/ HYD-ISDN combination and MRAs respectively, while 19%, 8.2% and 94% of the patients attained 100% of the target dose for beta blockers, RAS blockers/ HYD-ISDN combination and MRAs respectively.

CONCLUSIONS

Reasons behind GDMT non-prescribing were frequent and not clearly obvious in patients' medical notes. The majority of the patients were prescribed GDMT. However, dose optimization, specifically for beta blockers and RAS blockers/ HYD-ISDN combination, was still suboptimal. The findings should be interpreted in the context of low study power and that future studies, with larger sample sizes, are warranted to minimize this limitation.

摘要

背景目的

确定阿曼射血分数降低(<40%)的心力衰竭(HFrEF)患者未进行指南指导的药物治疗(GDMT)的原因、排除对GDMT不耐受者前后的药物使用情况以及剂量优化情况。

方法

该研究纳入了2016年1月至2019年12月期间在阿曼马斯喀特苏丹卡布斯大学医院门诊就诊的HFrEF患者,并随访至2021年6月底。根据欧洲、美国和加拿大的心力衰竭指南评估肾素-血管紧张素系统(RAS)阻滞剂(血管紧张素转换酶抑制剂(ACEI)或血管紧张素II受体阻滞剂(ARB)或血管紧张素受体脑啡肽酶抑制剂(ARNI))、β受体阻滞剂和盐皮质激素受体拮抗剂(MRA)的使用情况。采用单变量统计进行分析。

结果

本研究共纳入171例HFrEF患者,队列的总体平均年龄为63±15岁,59%为男性。超过65%的患者患有慢性肾脏病。近55%的患者对GDMT不耐受。在排除对GDMT不耐受的患者之前和之后,使用β受体阻滞剂、RAS阻滞剂/肼屈嗪-硝酸异山梨酯组合和MRA的患者比例分别为89%、97%和77%,以及94%、47%和85%,而同时使用GDMT组合的患者比例分别为41%和83%。分别有61%、44%和100%的患者接受了β受体阻滞剂、RAS阻滞剂/HYD-ISDN组合和MRA的≥50%目标剂量处方,而分别有19%、8.2%和94%的患者达到了β受体阻滞剂、RAS阻滞剂/HYD-ISDN组合和MRA的100%目标剂量。

结论

在患者病历中,未进行GDMT的原因很常见且不明显。大多数患者接受了GDMT治疗。然而,剂量优化,特别是β受体阻滞剂和RAS阻滞剂/HYD-ISDN组合的剂量优化,仍然不理想。这些发现应结合研究效能较低的背景来解释,未来有必要进行更大样本量的研究以尽量减少这一局限性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/26c1/9296089/ace19e91bab4/pharmpract-20-2642-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验